Eyenovia Inc is a biotechnology company focused on developing innovative ophthalmic therapeutics utilizing its proprietary delivery technology
The company aims to enhance the treatment of various eye conditions through its advanced product pipeline, which includes specialty pharmaceutical formulations designed to improve the efficacy and patient compliance of eye care treatments. Eyenovia’s pioneering approach leverages microdosing technology to deliver medications more precisely and effectively, potentially transforming the landscape of ocular therapeutics and improving outcomes for patients with vision-related ailments.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Eyenovia's Phase 3 CHAPERONE study fails to meet its primary endpoint, prompting a review of strategic alternatives, including potential mergers or asset sales.
Eyenovia shares are surging Monday in response to the company's announcement of the launch of a new FDA-approved ophthalmic drug in collaboration with Formosa Pharmaceuticals.
Eyenovia (stock surges with high trading volume after announcing a $5.14 million offering to fund commercialization of Mydcombi, pediatric myopia research, and debt repayment.
Eyenovia shares are trading lower by 35% Wednesday morning. The company announced plans to sell shares or pre-funded warrants in a best efforts offering.
